Quintiles, the world's largest CRO, is expecting its revenue to jump as much as 8.5% in 2016 on the heels of a record year.
Paula Brown Stafford, a 30-year-veteran of Quintiles, is planning to retire from the world's largest CRO at the end of the year, wrapping up her tenure as president of clinical development.
The globe's largest clinical research organization is looking to India as a source for the next waves of biosimilars as $55 billion worth of biotech drugs face patent expirations.
Quintiles, which has signed deep-seated R&D deals with some major players in biopharma, is extending the same all-encompassing development help to the rest of the industry, marketing a service through which the CRO takes a seat at the decisionmaking table.
Quintiles has made changes to Apple's open-source ResearchKit framework. The CRO made the enhancements--the code for which it released on the GitHub repository--to make Apple's platform more suitable for the trials it oversees.
Quintiles has contributed some open-source code to improve Apple's ResearchKit project, a platform designed to help physicians and scientists gather medical data from millions of patients.
Quintiles founder Dennis Gillings is set to vacate his chairmanship at the end of 2015, ending a 33-year tenure at the top that saw the North Carolina company grow into the world's biggest CRO.
Quintiles has contributed open-source enhancements to Apple's ResearchKit, adding more sophisticated application features beyond the basic three modules first introduced by Apple in March. The CRO plans to develop patient engagement ResearchKit-based apps for use in its own clinical trials with a particular focus on neurodegenerative diseases including dementia.
CRO giant Quintiles posted another $1 billion revenue quarter on the way to a record year, but the company is narrowing its sales projections over ongoing foreign exchange issues.
Quintiles signed a deal with healthcare information giant IMS Health to pair its own clinical development expertise with its partner's huge trove of real-world data, planning to use anonymized patient information to steer drug trials.